Mary Beth Schulte
Known title: DirectorCIK: 0001984252
Mary Beth Schulte's purchase track record
Mary Beth Schulte has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/23/2023 | ABX | $101K | -6.2% | +63.0% | +12.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ABX | ▲ Buy | Grant | 20,792 | $210K | 3/12/2026 | View on chart |
| ABX | ▲ Buy | Grant | 12,278 | $0 | 4/2/2025 | View on chart |
| ABX | ▲ Buy | Grant | 9,000 | $0 | 11/9/2023 | View on chart |
| ABX | ▲ Buy | Open Market | 13,000 | $101K | 8/23/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Abacus Global Management to Report Q3 2026 Results Nov 5
Abacus Global Management is scheduled to release its third-quarter 2026 financial results on November 5. The company also announced a partnership to integrate its LifeARC product into the Retirable platform. These developments provide upcoming catalysts for the stock, which is currently trading near its 52-week low.
Abacus Global Management to Report Q3 2026 Results Nov 5. Abacus Global Management is scheduled to release its third-quarter 2026 financial results on November 5. The company also announced a partnership to integrate its LifeARC product into the Retirable platform. These developments provide upcoming catalysts for the stock, which is currently trading near its 52-week low.